Elevated insular glutamate in fibromyalgia is associated with experimental pain

Arthritis and Rheumatism

Volumn 60, Issue 10, 2009, Pages 3146-3152

  Harris, Richard E ^a   Sundgren, Pia C ^a   Craig, A D ^b   Kirshenbaum, Eric ^a   Sen, Ananda ^a   Napadow, Vitaly ^c   Clauw, Daniel J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; GLUTAMINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROMYALGIA; GLUTAMATERGIC NEUROTRANSMISSION; HUMAN; INSULA; METABOLITE; NEUROTRANSMISSION; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PRESSURE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REST;

ADULT; CASE-CONTROL STUDIES; CEREBRAL CORTEX; FEMALE; FIBROMYALGIA; GLUTAMIC ACID; GLUTAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PAIN; PAIN THRESHOLD;

EID: 70349776233     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24849     Document Type: Article

References (32)

1. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992;19:846-850
2. Clauw DJ, Chrousos GP. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134-153
3. Arnold LM, Pritchett YL, D'Souza DN, Kajdasz DK, Iyengar S, Wernicke JF. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007;16:1145-1156 (Pubitemid 47587341)
4. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al, and the Pregabalin 1008-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-1273
5. Vitton O, Gendreau M, Gendreau J, Kranzler J, Rao SG. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004;19:S27-35. (Pubitemid 39386317)
6. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
7. Jacobsen S, Bredkjaer SR. The prevalence of fibromyalgia and widespread chronic musculoskeletal pain in the general population. Scand J Rheumatol 1992;21:261-263
8. Raspe H, Baumgartner C, Wolfe F. The prevalence of fibromyalgia in a rural German community: how much difference do different criteria make? [abstract]. Arthritis Rheum 1993;36 Suppl 9:S48.
9. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-1343 (Pubitemid 34525843)
10. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004;31:364-378 (Pubitemid 38160761)
11. Petzke F, Clauw DJ, Ambrose K, Khine A, Gracely RH. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-413 (Pubitemid 37186903)
12. Peres MF, Zukerman E, Senne Soares CA, Alonso EO, Santos BF, Faulhaber MH. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia 2004;24:735-739 (Pubitemid 39209077)
13. Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-211
14. Graven-Nielsen T, Aspegren KS, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-491 (Pubitemid 30214177)
15. Cohen SP, Verdolin MH, Chang AS, Kurihara C, Morlando BJ, Mao J. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain 2006;7:391-398 (Pubitemid 44208832)
16. Harris RE, Sundgren PC, Pang Y, Hsu M, Petrou M, Kim SH, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008;58:903-907
17. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-172
18. Brooks JC, Nurmikko TJ, Bimson WE, Singh KD, Roberts N. fMRI of thermal pain: effects of stimulus laterality and attention. Neuroimage 2002;15:293-301.
19. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30: 672-679
20. Petzke F, Gracely RH, Park KM, Ambrose K, Clauw DJ. What do tender points measure? Influence of distress on 4 measures of tenderness. J Rheumatol 2003;30:567-574 (Pubitemid 36301951)
21. Petzke F, Harris RE, Williams DA, Clauw DJ, Gracely RH. Differences in unpleasantness induced by experimental pressure between patients with fibromyalgia and controls. Eur J Pain 2005;9:325-335 (Pubitemid 40615712)
22. Craig AD, Chen K, Bandy D, Reiman EM. Thermosensory activation of insular cortex. Nat Neurosci 2000;3:184-190
23. Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 2002;3: 655-666
24. Singer T, Seymour B, O'Doherty J, Kaube H, Dolan RJ, Frith CD. Empathy for pain involves the affective but not sensory components of pain. Science 2004;303:1157-1162 (Pubitemid 38233574)
25. Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? [editorial]. Arthritis Rheum 2002;46:1136-1138
26. Mullins PG, Rowland LM, Jung RE, Sibbitt WL Jr. A novel technique to study the brain's response to pain: proton magnetic resonance spectroscopy. Neuroimage 2005;26:642-646
27. Helms G, Ciumas C, Kyaga S, Savic I. Increased thalamus levels of glutamate and glutamine (Glx) in patients with idiopathic generalised epilepsy. J Neurol Neurosurg Psychiatry 2006;77:489-494
28. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006;70:467-476 (Pubitemid 44092307)
29. Beydoun A, Nasreddine W, Atweh S. Efficacy and tolerability of pregabalin in partial epilepsy. Expert Rev Neurother 2008;8: 1013-1024 (Pubitemid 351962069)
30. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ. Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med 2004;51:435-440 (Pubitemid 38298653)
31. Schubert F, Gallinat J, Seifert F, Rinneberg H. Glutamate concentrations in human brain using single voxel proton magnetic resonance spectroscopy at 3 Tesla. Neuroimage 2004;21:1762-1771 (Pubitemid 38446596)
32. Wood PB, Ledbetter CR, Glabus MF, Broadwell LK, Patterson JC. Hippocampal metabolite abnormalities in fibromyalgia: correlation with clinical features. J Pain 2009;10:47-52.